DRAFT – JULY 25

AD HOC Announcement According to §15 WpHG

**Qiagen N.V.:**

QIAGEN publishes results for second quarter of 2011 and provides updated guidance for 2011

**Venlo, The Netherlands, July 25, 2011** – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced results of operations for the second quarter and first half of 2011.

Net sales in the second quarter rose 7% (+1% at constant exchange rates, or CER) to $282.2 million from the second quarter of 2010. Adjusted operating income grew 8% to $78.7 million, as the adjusted operating income margin remained steady at 28% of net sales. Adjusted net income grew 5% to $55.0 million in the 2011 period from $52.5 million in 2010. Adjusted diluted earnings per share rose to $0.23 in the 2011 quarter from $0.22 in the second quarter of 2010. Free cash flow in the second quarter improved 31% to $37.8 million over the year-ago period.

In the first half of 2011, net sales rose 4% to $546.4 million from the same period of 2010. Adjusted operating income rose 2% to $149.2 million from $146.7 million in the first half of 2010, with the adjusted operating income margin declining to 27% of net sales from 28% in the 2010 period. Adjusted net income was up 3% to $104.5 million in the 2011 period from $101.9 million in the first half of 2010. Adjusted diluted earnings per share rose to $0.43 in the first half of 2011 from $0.42 in the first half of 2010.

QIAGEN also updated its expectations for 2011 to incorporate the impact of acquisitions of Cellestis and Ipsogen, as well as based on the adverse impact of continued challenging market conditions. For the second half of 2011, QIAGEN expects total sales growth of approximately 7% CER of which approximately half is expected to come from organic growth. For the full year 2011, QIAGEN now expects total sales growth of approximately 3% CER with contributions from both organic growth and acquisitions. Adjusted diluted earnings per share (EPS) are expected to be approximately $0.96 for 2011, which includes previously announced expectations for dilution of approximately $0.03 per share related to planned investments and product migrations as part of the acquisitions of Cellestis and Ipsogen. (Net sales for 2010 were $1,087 million and adjusted diluted earnings per share were $0.93.)

A release containing the quarterly report has been published on the Company’s website at [www.qiagen.com](http://www.qiagen.com). Reconciliations of reported results to adjusted results are included in the tables accompanying this release.

Contact: Dr. Solveigh Mähler, QIAGEN N.V., Tel: +49 2103 29 11710; ir@qiagen.com